Omeros Reports Strong Q2 Earnings with Yartemlia Sales Growth and Debt Reduction
Omeros Corporation (OMER) reported strong second-quarter results for 2026, driven by significant growth in sales of its drug Yartemlia. Gross sales reached $32.2 million, a 190% increase from the first quarter, while net sales were $28.5 million after adjustments primarily due to chargebacks and distribution fees. The company reported a net income of $13.2 million or $0.18 per share, largely influenced by an $11.5 million non-cash gain on derivatives. Non-GAAP adjusted net income was $1.8 million, up from a loss in the previous quarter. Omeros also improved its liquidity with cash and short-term investments totaling $132 million. The company repurchased 489,000 shares at an average price of $11.70 per share during Q2 and reduced debt by 43% through the repurchase of convertible notes worth $30.5 million in principal.
Tickers: $OMER
Topics: debt_reduction financial_performance pharmaceuticals stock_repurchase